Horrobin DF (1987) Essential fatty acids, prostaglandins, and alcoholism: An overview. Alcohol Clin Exp Res 11: 2–9.
[2]
Valles SL, Blanco AM, Pascual M, Guerri C (2004) Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathol 14: 365–371.
[3]
Das UN (2002) The alcohol consumption and dementia. Lancet 360: 490.
[4]
Das UN (2005) COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit 11: RA233–RA237.
[5]
Garcia MC, Kim HV (1007) Mobilization of arachidonate and docosahexaenoate by stimulation of the 5-HT2A receptor in rat C6 glioma cells. Brain Res 768: 43–48.
[6]
Lengqvist J, Mata de Urquiza A, Bergman AC, Willson TM, Sjovall J, et al. (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290: 2140–2144.
[7]
Gamoh S, Hashimoto M, Hossain S, Masumura S (2001) Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 28: 266–270.
[8]
Saareks V, Mucha I, Sievi E, Riutta A (1999) Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol Toxicol 84: 274–280.
[9]
Ieraci A, Herrera DG (2006) Nicotinamide protects against ethanol-induced apoptotic neurodegeneration in the developing mouse brain. PLoS Med 3: e101. doi: 10.1371/journal.pmed.0030101.
